Intermedin Is a Calcitonin/Calcitonin Gene-related Peptide Family Peptide Acting through the Calcitonin Receptor-like Receptor/Receptor Activity-modifying Protein Receptor Complexes
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Calcitonin, calcitonin gene-related peptide (CGRP), adrenomedullin (ADM), and amylin belong to a unique group of peptide hormones important for homeostasis in diverse tissues. Calcitonin is essential for calcium balance, whereas CGRP and ADM are important for neurotransmission and cardiovascular and respiratory regulation. Based on phylogenetic analysis, we identified intermedin as a novel member of the calcitonin/CGRP peptide family. Analysis of intermedin expression indicated that intermedin is expressed primarily in the pituitary and gastrointestinal tract. Intermedin increased cAMP production in SK-N-MC and L6 cells expressing endogenous CGRP receptors and competed with labeled CGRP for binding to its receptors in these cells. In addition, treatment of 293T cells expressing recombinant calcitonin receptor-like receptor (CRLR) and one of the three receptor activity-modifying proteins (RAMPs) showed that a CRLR/RAMP receptor complex is required for intermedin signaling. In contrast to CGRP and ADM, which exhibited a preferential stimulation of CRLR when co-expressed with RAMP1 and RAMP2 or RAMP3, respectively, intermedin represents a nonselective agonist for the RAMP coreceptors. In vivo studies demonstrated that intermedin treatment led to blood pressure reduction in both normal and spontaneously hypertensive rats via interactions with the CRLR/RAMP receptor complexes. Furthermore, in vivo treatment in mice with intermedin led to suppression of gastric emptying activity and food intake. Thus, identification of intermedin as a novel member of the calcitonin/CGRP peptide family capable of signaling through CRLR/RAMP receptor complexes provides an additional player in the regulation of peripheral tissues by CRLR and will allow development of new therapeutic agents for pathologies associated with diverse vascular and gastrointestinal disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2004, two groups discovered the mammalian gene ADM2, which encodes a peptide with high similarity to adrenomedullin, and was named intermedin or adrenomedullin 2 (177, 195).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [177]
In the citing paper
“Roh et al. found that, in the rat, intermedin is primarily expressed in the pituitary and gastrointestinal tract and showed that intraperitoneal administration of intermedin decreased blood pressure in both normal and spontaneously hypertensive rats (98, 177).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [177]
In the citing paper
“Later studies have shown that CRLR/RAMP complex also functions as receptor for intermedin, which binds in a nonselective manner to either of the three RAMPs/CRLR dimers (177).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [177]
Citations
Cites
Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing
Rosenfeld, M. G., Mermod, J.-J., Amara, S. G., Swanson, L. W., Sawchenko, P. E., Rivier, J., Vale, W. W., & Evans, R. M. (1983) · Nature · doi:10.1038/304129a0 · Cited by 2,302
Adrenomedullin: A Novel Hypotensive Peptide Isolated from Human Pheochromocytoma
Kitamura, K., Kangawa, K., Kawamoto, M., Ichiki, Y., Nakamura, S., Matsuo, H., & Eto, T. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1451 · Cited by 2,192
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134
Amara, S. G., Jonas, V., Rosenfeld, M. G., Ong, E. S., & Evans, R. M. (1982) · Nature · doi:10.1038/298240a0 · Cited by 2,105
Reyes, T. M., Lewis, K., Perrin, M. H., Kunitake, K. S., Vaughan, J., Arias, C. A., Hogenesch, J. B., Gulyas, J., Rivier, J., Vale, W. W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051626398 · Cited by 887
Poyner, D. R., Sexton, P. M., Marshall, I., Smith, D. M., Quirion, R., Born, W., Muff, R., Fischer, J. A., & Foord, S. M. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.233 · Cited by 804
Activation of Orphan Receptors by the Hormone Relaxin
Hsu, S. Y., Nakabayashi, K., Nishi, S., Kumagai, J., Kudo, M., Sherwood, O. D., & Hsueh, A. J. W. (2002) · Science · doi:10.1126/science.1065654 · Cited by 786
Self-citationHsu, S. Y., & Hsueh, A. J. W. (2001) · Nature Medicine · doi:10.1038/87936 · Cited by 650
Self-citationCloning and Characterization of cDNA Encoding a Precursor for Human Adrenomedullin
Kitamura, K., Sakata, J., Kangawa, K., Kojima, M., Matsuo, H., & Eto, T. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1881 · Cited by 605
Christopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., & Sexton, P. M. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.1.235 · Cited by 486
Research works printed but not linked: 7
- Copp, 1994, Clin. Investig. Med., 17, 268
- Mulder, 2000, Am. J. Physiol., 278, E684
- Chiba, 1989, Am. J. Physiol., 256, E331
- Eguchi, 1994, Endocrinology, 135, 2454, 10.1210/endo.135.6.7988431 · doi:10.1210/endo.135.6.7988431 · Paper page
- Reidelberger, 2002, Am. J. Physiol., 282, R1395
- Hsu, 2002, Mol. Endocrinol., 16, 1538, 10.1210/mend.16.7.0871 · doi:10.1210/mend.16.7.0871 · Paper page
- Meeran, 1997, J. Clin. Endocrinol. Metab., 82, 95
Cited by
Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes Mellitus
Westermark, P., Andersson, A., & Westermark, G. T. (2011) · Physiological Reviews · doi:10.1152/physrev.00042.2009 · Cited by 1,044
“The 37-amino acid residue peptide IAPP belongs to the calcitonin family, which also contains calcitonin, CGRP, adrenomedullin, and intermedin (312, 414).”
BackgroundStomach regulates energy balance via acylated ghrelin and desacyl ghrelin
Asakawa, A., Inui, A., Fujimiya, M., Sakamaki, R., Shinfuku, N., Ueta, Y., Meguid, M. M., & Kasuga, M. (2005) · Gut · doi:10.1136/gut.2004.038737 · Cited by 483
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Russo, A. F., & Hay, D. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00059.2021 · Cited by 382
Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25
Hay, D. L., Garelja, M. L., Poyner, D. R., & Walker, C. S. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14075 · Cited by 370
“AM2 or IMD was initially described by two different research groups (Roh et al., 2004; Takei et al., 2004).”
BackgroundLennerz, J. K., Rühle, V., Ceppa, E. P., Neuhuber, W. L., Bunnett, N. W., Grady, E. F., & Messlinger, K. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21607 · Cited by 325
“Intracranial functions of AMD and the AMD peptide homolog intermedin seem to be confined to vascular receptors (Edvinsson et al., 2001; Roh et al., 2004; Taylor et al., 2005a,b; Juhl et al., 2006).”
BackgroundHormones and Disorders of Mineral Metabolism
Bringhurst, F. R., Demay, M. B., & Kronenberg, H. M. (2011) · Williams Textbook of Endocrinology · doi:10.1016/b978-1-4377-0324-5.00028-6 · Cited by 298
A novel diuretic hormone receptor in Drosophila: evidence for conservation of CGRP signaling
Johnson, E. C., Shafer, O. T., Trigg, J. S., Park, J., Schooley, D. A., Dow, J. A., & Taghert, P. H. (2005) · Journal of Experimental Biology · doi:10.1242/jeb.01529 · Cited by 254
“…for the neuropeptide intermedin (also referred to as adrenomedullin 2; Takei et al., 2004), which is related to CGRP. RAMP co-expression with CLR in HEK cells permitted functional responses, but RAMP subtype did not alter the pharmacological response of the CLR to intermedin (Roh et al., 2004).”
BackgroundParacrinicity: The Story of 30 Years of Cellular Pituitary Crosstalk
Denef, C. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2007.01616.x · Cited by 244
Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases
Carniglia, L., Ramírez, D., Durand, D., Saba, J., Turati, J., Caruso, C., Scimonelli, T. N., & Lasaga, M. (2017) · Mediators of Inflammation · doi:10.1155/2017/5048616 · Cited by 231
Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes
Hay, D. L., Christopoulos, G., Christopoulos, A., Poyner, D. R., & Sexton, P. M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008615 · Cited by 210
“In support of the weak effect of AM at these receptors (Table 1), AM22-52, an antagonist of AM receptors, had no effect at either CT or AMY receptors (Table 3).”
BackgroundInfluentialAmylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo
Dacquin, R., Davey, R. A., Laplace, C., Levasseur, R., Morris, H. A., Goldring, S. R., Gebre-Medhin, S., Galson, D. L., Zajac, J. D., & Karsenty, G. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200312135 · Cited by 206
Neuropeptides and their receptors: innovative science providing novel therapeutic targets
Brain, S. D., & Cox, H. M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706461 · Cited by 197
“The structure of intermedin is highly conserved across species, but has only about 15% sequence similarity to the other CGRP peptides (Roh et al., 2004).”
BackgroundThe role of peptides and receptors of the calcitonin family in the regulation of bone metabolism
Naot, D., & Cornish, J. (2008) · Bone · doi:10.1016/j.bone.2008.07.003 · Cited by 182
“In addition to the ligands detailed in Table 1, adrenomedullin 2 binds with high affinity in a non-selective manner to combinations of CLR with any of the RAMPs [9].”
BackgroundAdrenomedullin: A Protective Factor for Blood Vessels
Kato, J., Tsuruda, T., Kita, T., Kitamura, K., & Eto, T. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000184759.91369.f8 · Cited by 164
Abraham, H. M. A., Wolfson, L., Moscufo, N., Guttmann, C. R. G., Kaplan, R. F., & White, W. B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.121 · Cited by 146
“Adrenomedullin 2 stimulates cyclic AMP production and has a potent vasodilator action.(27,28) After adjusting for age, sex, body mass index, ambulatory blood pressure (BP), use of antihypertensive medications, presence of diabetes mellitus, chronic kidney and cardiac disease, smoking, and alcohol intake, the OR for WM…”
BackgroundVascular leak in sepsis: physiological basis and potential therapeutic advances
McMullan, R. R., McAuley, D. F., O’Kane, C. M., & Silversides, J. A. (2024) · Critical Care · doi:10.1186/s13054-024-04875-6 · Cited by 166
“Intermedin is a member of the calcitonin gene related peptide family which exerts its effects via the calcitonin receptor-like receptor signalling pathway [158].”
BackgroundThe pharmacology of Adrenomedullin 2/Intermedin
Hong, Y., Hay, D. L., Quirion, R., & Poyner, D. R. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01530.x · Cited by 144
“Generally, this peptide is found in the brain, pituitary, heart, kidney, gastrointestinal tract, plasma (Roh et al., 2004; Takei et al., 2004a; Taylor et al. 2005; Takahashi et al., 2006), pancreas, lung, spleen, thymus and ovary (Takei et al., 2004b).”
BackgroundMethodInfluentialThe Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
Song, J.-Q., Teng, X., Cai, Y., Tang, C., & Qi, Y. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0398-7 · Cited by 139
“IMD represents a nonselective agonist for the CRLR/RAMP complex and exerts its biological effects through activating the CRLR/RAMP system and elevating the intracellular cAMP level [1, 15].”
BackgroundMethodInfluentialCalcitonin gene-related peptide (CGRP) and its role in hypertension
Smillie, S.-J., & Brain, S. D. (2011) · Neuropeptides · doi:10.1016/j.npep.2010.12.002 · Cited by 137
“, 1993), intermedin (AM2), (Roh et al., 2003) and amylin (Amy), (Westermark et al.”
Bomberger, J. M., Parameswaran, N., Hall, C. S., Aiyar, N., & Spielman, W. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413786200 · Cited by 121
Intramembrane receptor–receptor interactions: a novel principle in molecular medicine
Fuxe, K., Canals, M., Torvinen, M., Marcellino, D., Terasmaa, A., Genedani, S., Leo, G., Guidolin, D., Diaz-Cabiale, Z., Rivera, A., et al. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-006-0589-0 · Cited by 118
“…that the receptor activity-modifying proteins (RAMP) regulate the pharmacology of the receptors for the calcitonin family of peptide hormones (McLatchie et al., 1998; see also Foord et al., 2005) like calcitonin gene-related peptide (CGRP), adrenomedullin (ADM) and intermedin (Roh et al., 2004).”
Bell, D., & McDermott, B. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707494 · Cited by 115
“A weak antagonistic effect of AM22–52 on IMD response was demonstrated in SHR; the effect of this fragment was not examined in normotensive animals (Roh et al., 2004).”
BackgroundInfluentialPathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders
Ishimitsu, T., Ono, H., Minami, J., & Matsuoka, H. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.004 · Cited by 119
Cottrell, G. S., Roosterman, D., Marvizon, J.-C., Song, B., Wick, E., Pikios, S., Wong, H., Berthelier, C., Tang, Y., Sternini, C., et al. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20669 · Cited by 104
Majesky, M. W. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310223 · Cited by 112
Mechanisms and treatment of obesity-related hypertension—Part 1: Mechanisms
Parvanova, A. I., Reseghetti, E., Abbate, M., & Ruggenenti, P. L. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad282 · Cited by 120
“Table 2 shows evidence for a modulatory role of in-termedin and adrenomedullin( cardiovascular peptides from the CGRP superfamily [116 –121 ]) in BP reduction through attenuation of sympatho-excitation in obesity.”
BackgroundChang, C. L., Roh, J., & Hsu, S. Y. (2004) · Peptides · doi:10.1016/j.peptides.2004.05.021 · Cited by 102
Self-citationSchnoor, M., Ponce, A. G., Vadillo, E., Pelayo, R., Rossaint, J., & Zarbock, A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2449-x · Cited by 101
Novel fish-derived adrenomedullin in mammals: structure and possible function
Takei, Y., Hyodo, S., Katafuchi, T., & Minamino, N. (2004) · Peptides · doi:10.1016/j.peptides.2004.06.026 · Cited by 100
RAMPs: the past, present and future
Parameswaran, N., & Spielman, W. S. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.09.006 · Cited by 108
Weston, C., Winfield, I., Harris, M., Hodgson, R., Shah, A., Dowell, S. J., Mobarec, J. C., Woodlock, D. A., Reynolds, C. A., Poyner, D. R., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.751362 · Cited by 95
Taylor, M. M., Bagley, S. L., & Samson, W. K. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00744.2004 · Cited by 95
“Indeed, like AM (7) and CGRP (5), IMD had potent hypotensive effects when administered intraperitoneally (ip) (20) or intravenously (iv) (26), which could be at least partially blocked by AM and CGRP receptor antagonists (20).”
InfluentialCalcitonin gene‐related peptide ( CGRP ): A novel target for Alzheimer's disease
Singh, Y. P., Gupta, G., Shrivastava, B., Dahiya, R., Tiwari, J., Ashwathanarayana, M., Sharma, R. K., Agrawal, M., Mishra, A., & Dua, K. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12696 · Cited by 93
Adrenomedullin – new perspectives of a potent peptide hormone
Schönauer, R. A.-R., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2017) · Journal of Peptide Science · doi:10.1002/psc.2953 · Cited by 89
Molecular studies of CGRP and the CGRP family of peptides in the central nervous system
Hendrikse, E. R., Bower, R. L., Hay, D. L., & Walker, C. S. (2018) · Cephalalgia · doi:10.1177/0333102418765787 · Cited by 90
Calcitonin and calcitonin receptor‐like receptors: common themes with family B GPCRs?
Barwell, J., Gingell, J. J., Watkins, H. A., Archbold, J. K., Poyner, D. R., & Hay, D. L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01525.x · Cited by 80
“The calcitonin (CT) family of peptides consists of six members: CT, amylin, adrenomedullin (AM), two distinct forms of calcitonin gene-related peptide (aCGRP and bCGRP), and AM2, also known as intermedin (Roh et al., 2004).”
BackgroundChang, J. R., Guo, J. F., Wang, Y., Hou, Y., Lu, W., Zhang, J. S., Yu, Y. R., Xu, M. J., Liu, X., Wang, X. J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.029 · Cited by 86
Adrenomedullin and tumour microenvironment
Larráyoz, I. M., Martínez-Herrero, S., García-Sanmartín, J., Ochoa‐Callejero, L., & Martínez, A. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0339-2 · Cited by 86
“It belongs to the amylin/calcitonin gene-related peptide (CGRP) super-family, which also includes CGRP, amylin and intermedin, also named adrenomedullin 2 [5-7].”
BackgroundBomberger, J. M., Spielman, W. S., Hall, C. S., Weinman, E. J., & Parameswaran, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501751200 · Cited by 75
Intermedin protects against renal ischemia-reperfusion injury by inhibition of oxidative stress
Qiao, X., Li, R., Li, H., Zhu, G., Huang, X.-G., Shan, S., & Bai, B. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00054.2012 · Cited by 76
“IMD shares structural and functional homology with adrenomedullin (30, 38), which can attenuate renal IRI (27).”
Calcitonin and Bone Physiology: In Vitro, In Vivo, and Clinical Investigations
Xie, J., Guo, J., Kanwal, Z., Wu, M., Lv, X., Ibrahim, N. A., Li, P., Buabeid, M. A., Arafa, E. A., & Sun, Q. (2020) · International Journal of Endocrinology · doi:10.1155/2020/3236828 · Cited by 83
“Additionally, this CRLR/RAMP complex can behave as a receptor for intermedin, which in result, indiscriminately interacts with one of the three RAMPs or CRLR dimers [43].”
BackgroundOgoshi, M., Inoue, K., Naruse, K., & Takei, Y. (2006) · Peptides · doi:10.1016/j.peptides.2006.09.011 · Cited by 82
Intermedin protects against myocardial ischemia-reperfusion injury in diabetic rats
Li, H., Bian, Y., Zhang, N., Guo, J., Wang, C., Lau, W. B., & Xiao, C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-91 · Cited by 78
Hay, D. L., Walker, C. S., & Poyner, D. R. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0244 · Cited by 80
Effects of intermedin1–53 on cardiac function and ischemia/reperfusion injury in isolated rat hearts
Yang, J., Jia, Y.-X., Pan, C., Zhao, J., Ouyang, M., Yang, J., Chang, J., Tang, C., & Qi, Y. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.071 · Cited by 73
Modulating receptor function through RAMPs: can they represent drug targets in themselves?
Sexton, P. M., Poyner, D. R., Simms, J., Christopoulos, A., & Hay, D. L. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.12.009 · Cited by 81
Shared and separate functions of the RAMP-based adrenomedullin receptors
Kuwasako, K., Kitamura, K., Nagata, S., Hikosaka, T., Takei, Y., & Kato, J. (2011) · Peptides · doi:10.1016/j.peptides.2011.05.022 · Cited by 76
Qi, T., Christopoulos, G., Bailey, R. J., Christopoulos, A., Sexton, P. M., & Hay, D. L. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047142 · Cited by 73
“On the other hand, intermedin, in particular the short form (40 amino acids, IMDS), did not discriminate between the three RAMP/CL complexes (Roh et al., 2004; Hay et al., 2005).”
BackgroundAdrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues
Li, Y., Jiang, C., Wang, X., Zhang, Y., Shibahara, S., & Takahashi, K. (2007) · Peptides · doi:10.1016/j.peptides.2007.03.005 · Cited by 71
Bench-to-bedside pharmacology of adrenomedullin
Kato, J., & Kitamura, K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.06.061 · Cited by 79
“1 (Cooper et al., 1987; Kato and Kitamura, 2013; Roh et al., 2004; Takei et al., 2004).”
Mao, S., Fan, X., Xue, F., Chen, R., Chen, X., Yuan, G., Hu, L.-G., Liu, S. F., & Gong, Y. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.06.004 · Cited by 70
Intermedin is a new angiogenic growth factor
SMITH, R. S., Gao, L., Bledsoe, G., Chao, L., & Chao, J. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00404.2009 · Cited by 67
“Like AM, IMD is expressed in many organs of the body, including the gastrointestinal tract, pancreas, and lung (3, 26, 30).”
BackgroundIntermedin Suppresses Pressure Overload Cardiac Hypertrophy through Activation of Autophagy
Chen, H., Wang, X., Tong, M., Wu, D., Wu, S., Chen, J., Wang, X., Wang, X.-L., Kang, Y., Tang, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064757 · Cited by 66
“We further supplemented exogenous IMD, which has the same molecular structure and bioactivity as the wild type IMD peptide [15], to hypertrophic animals and cells, to reveal the regulation of IMD in cardiac hypertrophy.”
MethodInfluentialMarvizón, J. C. G., Pérez, O. A., Song, B., Chen, W., Bunnett, N. W., Grady, E. F., & Todd, A. J. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.05.036 · Cited by 66
“It would be important to study the colocalization of RAMP2 and RAMP3 with CRLR in the dorsal horn using reliable antibodies.”
BackgroundInfluentialAdrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases
Zhang, S., Xu, M., & Wang, X. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13814 · Cited by 66
“The overall rank of the hypotensive potency is ADM2/IMD1–53 > ADM > ADM2/ IMD1–47 = CGRP > ADM2/IMD1–40, which can be blocked by CGRP receptor antagonist (Roh et al., 2004; Taylor et al., 2005a; Jolly et al., 2009).”
BackgroundInfluentialNejabati, H. R., Latifi, Z., Ghasemnejad, T., Fattahi, A., & Nouri, M. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1318375 · Cited by 65
Takahashi, K., Kikuchi, K., Maruyama, Y., Urabe, T., Nakajima, K., Sasano, H., Imai, Y., Murakami, O., & Totsune, K. (2005) · Peptides · doi:10.1016/j.peptides.2005.11.004 · Cited by 65
Granholm, S., Lundberg, P., & Lerner, U. H. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0338 · Cited by 63
“2000, 2003, 2004, Chang et al .”
Expression of adrenomedullin2/intermedin in human brain, heart, and kidney
Morimoto, R., Satoh, F., Murakami, O., Totsune, K., Suzuki, T., Sasano, H., Ito, S., & Takahashi, K. (2007) · Peptides · doi:10.1016/j.peptides.2007.01.018 · Cited by 63
Muff, R., Born, W., Lutz, T. A., & Fischer, J. A. (2004) · Peptides · doi:10.1016/j.peptides.2004.08.007 · Cited by 62
Pfeil, U., Aslam, M., Paddenberg, R., Quanz, K., Chang, C. L., Park, J., Gries, B., Rafiq, A., Faulhammer, P., Goldenberg, A., et al. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90608.2008 · Cited by 67
“In other cell types IMD mediates most of its effects via activation of PKA pathway (33).”
InfluentialSelf-citationDong, Y.-L., Green, K. E., Vegiragu, S., Hankins, G. D. V., Martin, E., Chauhan, M., Thota, C., & Yallampalli, C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1481 · Cited by 68
Cardiovascular effects of newly discovered peptide intermedin/adrenomedullin 2
Pan, C., Yang, J., Cai, D.-Y., Zhao, J., Gerns, H., Yang, J., Chang, J., Tang, C., & Qi, Y. (2005) · Peptides · doi:10.1016/j.peptides.2005.02.013 · Cited by 60
Sonne, N., Karsdal, M. A., & Henriksen, K. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101109 · Cited by 63
Xiao, F., Wang, D., Kong, L., Li, M., Feng, Z., Shuai, B., Wang, L., Wei, Y., Li, H., Wu, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05062-2 · Cited by 58
Nrf2/HO-1 as a therapeutic target in renal fibrosis
Hassanein, E. H. M., Ibrahim, I. M., Abd‐alhameed, E. K., Sharawi, Z. W., Jaber, F. A., & Althagafy, H. S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122209 · Cited by 65
Dai, X.-Y., Cai, Y., Mao, D.-D., Qi, Y., Tang, C., Xu, Q., Zhu, Y., Xu, M., & Wang, X. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.07.006 · Cited by 64
“IMD, a novel peptide of the CGRP family, is widely expressed in the body and acts non-selectively on both CGRP and adrenomedullin receptors [25,36], which are richly expressed in macrophages, as seen by PCR and western blot analysis (data not shown).”
BackgroundNikitenko, L. L., Blucher, N., Fox, S. B., Bicknell, R., Smith, D. M., & REES, M. C. P. (2006) · Journal of Cell Science · doi:10.1242/jcs.02783 · Cited by 60
“S1) (Poyner et al., 2002; Roh et al., 2004).”
Aslam, M., Pfeil, U., Gündüz, D., Rafiq, A., Kummer, W., Piper, H. M., & Noll, T. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01540.x · Cited by 56
“…studies show that adrenomedullin is an agonist for CLR/RAMP2 and RAMP3 (Fraser et al., 1999; Takei et al., 2004a), whereas intermedin signals mainly through CLR associated with RAMP1 or RAMP3, but also shows affinity towards RAMP2 (Roh et al., 2004; Takei et al., 2004a; Bell and McDermott, 2008).”
BackgroundResultInfluentialIntermedin 1− 53 Attenuates Abdominal Aortic Aneurysm by Inhibiting Oxidative Stress
Lu, W., Jia, L., Ni, X.-Q., Zhao, L., Chang, J.-R., Zhang, J., Hou, Y.-L., Zhu, Y., Guan, Y., Yu, Y.-R., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307825 · Cited by 55
“E-mail yongfenqi@163.com Intermedin1−53 Attenuates Abdominal Aortic Aneurysm by Inhibiting Oxidative Stress Wei-Wei Lu, Li-Xin Jia, Xian-Qiang Ni, Lei Zhao, Jin-Rui Chang, Jin-Sheng Zhang, Yue-Long Hou, Yi Zhu, You-Fei Guan, Yan-Rong Yu, Jie Du, Chao-Shu Tang, Yong-Fen Qi Intermedin (IMD), also known as ADM-2, is a pe…”
BackgroundTeng, X., Song, J.-Q., Zhang, G., Cai, Y., Yuan, F., Du, J., Tang, C., & Qi, Y. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0808-5 · Cited by 55
“A truncated IMD fragment (IMD17–47) can inhibit the IMD effects and is considered a nonselective functional antagonist of IMD action [9, 11].”
BackgroundGranholm, S., Lundberg, P., & Lerner, U. H. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21674 · Cited by 54
“CT belongs to a family of peptides, consisting of two calcitonin gene-related peptides (a-CGRP, b-CGRP), amylin (AMY), adrenomedullin (ADM), and the recently discovered intermedin/adrenomedullin2 (IMD) and calcitonin receptor activating peptides 1–3 (CRSP1–3) [Wimalawansa, 1997; Katafuchi et al., 2003a,b; Chang et al.…”
BackgroundInfluentialSong, J.-Q., Teng, X., Cai, Y., Tang, C., & Qi, Y. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0382-2 · Cited by 54
“IMD represents a nonselective agonist for the CRLR/RAMP complex and exerts its biological effects through activating the CRLR/RAMP system and elevating the intracellular cAMP level [1, 15].”
BackgroundMethodInfluentialLv, Y., Zhang, S.-Y., Liang, X., Zhang, H., Xu, Z., Liu, B., Xu, M.-J., Jiang, C., Shang, J., & Wang, X. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.735563 · Cited by 52
“Adrenomedullin 2 (ADM2), also known as intermedin, is an endogenous peptide discovered in 2004 and belongs to the calcitonin gene-related peptide (CGRP)/calcitonin family (21, 22).”
BackgroundMethodTransmembrane Signaling by G Protein–Coupled Receptors
Jacob, C., & Bunnett, N. W. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50006-4 · Cited by 54
Cai, W., Kim, C., Go, H., Egertová, M., Zampronio, C. G., Jones, A. M. E., Park, N. G., & Elphick, M. R. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00382 · Cited by 53
“More recently, other peptides that are related to calcitonin and CGRP have been identified inmammals, including βCGRP, amylin, adrenomedullin, adrenomedullin 2 (intermedin), and calcitonin receptor-stimulating peptide (CRSP), and a shared characteristic of all of these peptides is the presence of an N-terminal disulfi…”
BackgroundCai, Y., Xu, M., Teng, X., Zhou, Y. B., Chen, L., Zhu, Y., Wang, X., Tang, C., & Qi, Y. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp366 · Cited by 52
“ADM2) is a novel peptide of the calcitonin gene-related peptide (CGRP) family; the C-terminal region of this prepro-peptide encompasses a putative 47 amino-acid peptide sharing 28% sequence identity with ADM and ,20% with CGRP and is predicted to possess the common structural features characteristic of members of the…”
Sandoval-Talamantes, A. K., Gómez-González, B. A., Uriarte-Mayorga, D. F., Martinez-Guzman, M. A., Hidalgo, K. A. W., & Alvarado‐Navarro, A. (2019) · Neuropeptides · doi:10.1016/j.npep.2019.102004 · Cited by 59
Dong, F., Taylor, M. M., Samson, W. K., & Ren, J. T. (2006) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01631.2005 · Cited by 51
“IMD and the CRLR/RAMP complexes are expressed in myocardium (14, 17, 18, 26), indicating the peptide may act in an autocrine or paracrine manner to regulate heart function.”
BackgroundInfluentialOhtsu, H., Higuchi, S., Shirai, H., Eguchi, K., Suzuki, H., Hinoki, A., Brailoiu, E., Eckhart, A. D., Frank, G. D., & Eguchi, S. (2008) · Endocrinology · doi:10.1210/en.2007-1694 · Cited by 52
“YM-254890 up to 10 m did not interfere with an intracellular cAMP elevation in VSMCs induced by intermedin, a potent agonist for a family of Gs-coupled receptors (31) (Fig.”
BackgroundStress hormone secretion is altered by central administration of intermedin/adrenomedullin-2
Taylor, M. M., & Samson, W. K. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.034 · Cited by 50
Zhao, Y., Bell, D., Smith, L. R., Zhao, L., Devine, A. B., McHenry, E. M., Nicholls, D., & McDermott, B. J. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092783 · Cited by 50
“Intermedin acts nonselectively at all three RAMP-CLR coreceptors (Roh et al., 2004).”
BackgroundGlaser, S. S., Ueno, Y., DeMorrow, S., Chiasson, V. L., Katki, K. A., Venter, J. K., Francis, H., Dickerson, I. M., DiPette, D. J., Supowit, S. C., et al. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700602 · Cited by 50
“The concentration of α -CGRP and β -CGRP (1−9 M) used to stimulate purified mouse BDL cholangiocytes was in the range of that used in other in vitro studie”
MethodAdrenomedullin: Continuing to explore cardioprotection
Tsuruda, T., Kato, J., Kuwasako, K., & Kitamura, K. (2018) · Peptides · doi:10.1016/j.peptides.2018.03.012 · Cited by 49
Sabharwal, R., Zhang, Z., Lu, Y., Abboud, F. M., Russo, A. F., & Chapleau, M. W. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.148171 · Cited by 48
Taylor, M. M., Bagley, S. L., & Samson, W. K. (2005) · Endocrinology · doi:10.1210/en.2005-0949 · Cited by 47
Tache, Y. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803414097 · Cited by 46
Adrenomedullin and pregnancy: perspectives from animal models to humans
Lenhart, P., & Caron, K. M. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.02.007 · Cited by 53
Dumont, Y., Chabot, J., & Quirion, R. (2004) · Peptides · doi:10.1016/j.peptides.2004.01.013 · Cited by 49
Chang, J.-R., Duan, X.-H., Zhang, B., Teng, X., Zhou, Y., Liu, Y., Yu, Y.-R., Zhu, Y., Tang, C., & Qi, Y. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213502619 · Cited by 45
Wang, Y., Tian, J., Qiao, X., Su, X., Mi, Y., Zhang, R., & Li, R. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0157-7 · Cited by 48
“Intermedin (IMD), also called adrenomedullin 2 (ADM2), is a novel member of the calcitonin gene-related peptide (CGRP) superfamily [13, 14] and has been shown to have pathophysiological effects in multiple disease processes involving the circulatory and renal systems [15, 16, 23, 24].”
BackgroundAdrenomedullin – Current perspective on a peptide hormone with significant therapeutic potential
Fischer, J., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2020) · Peptides · doi:10.1016/j.peptides.2020.170347 · Cited by 44
Molecular and functional characterization of adrenomedullin receptors in pufferfish
Nag, K., Kato, A., Nakada, T., Hoshijima, K., Mistry, A. C., Takei, Y., & Hirose, S. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00507.2005 · Cited by 45
“Also in mammals, a second member, AM2 or intermedin (30, 37, 38), has been identified and shown to be a nonselective ligand for the receptor complexes of CLR and RAMP1–3.”
BackgroundChauhan, M., Yallampalli, U., Dong, Y.-L., Hankins, G. D. V., & Yallampalli, C. (2009) · Biology of Reproduction · doi:10.1095/biolreprod.108.074419 · Cited by 42
“Unlike ADM and CALCB, ADM2 is a nonselective agonist for RAMPs but exhibits greater potency with CALCRL/RAMP1 and CALCRL/RAMP3 [1].”
BackgroundResultInfluentialTakei, Y., Ogoshi, M., & Inoue, K. (2007) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2007.05.001 · Cited by 48
Role of neuropeptides in cardiomyopathies
Dvorakova, M. C., Kružliak, P., & Rabkin, S. W. (2014) · Peptides · doi:10.1016/j.peptides.2014.08.004 · Cited by 46
Kandilci, H. B., Gümüşel, B., & Lippton, H. L. (2008) · Peptides · doi:10.1016/j.peptides.2008.04.008 · Cited by 42
Uzan, B., Ea, H., Launay, J., Garel, J., Champy, R., Cressent, M., & Lioté, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5548 · Cited by 42
“peptide (CGRP), amylin, intermedin (12), and calcitonin.”
Metadata
- Authors
- Roh, J., Chang, C. L., Bhalla, A., Klein, C., & Hsu, S. Y. T.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Hsu, Sheau Yu Teddy
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 279
- Issue
- 8
- Pages
- 7264-7274
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2044285853
- Cited by
- 443
- References
- 37
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 7 · 2023: 12 · 2022: 15 · 2021: 16 · 2020: 17 · 2019: 15 · 2018: 22 · 2017: 25 · 2016: 23 · 2015: 20 · 2014: 22 · 2013: 24 · 2012: 24
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6102 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- School of Medicine, Stanford University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
- Keywords
- intermedin, calcitonin gene-related peptide, calcitonin, adrenomedullin, amylin, calcitonin receptor-like receptor, receptor activity-modifying proteins, RAMP1, RAMP2, RAMP3, cAMP signaling, blood pressure regulation, hypertension, gastric emptying, dietary intake, pituitary gland, gastrointestinal tract
- MeSH terms
- Cyclic AMP, Amino Acid Sequence, Animals, Base Sequence, Blood Pressure, Calcitonin, Cell Line, Cloning, Molecular, Dose-Response Relationship, Drug, Humans, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptides, Phylogeny, Protein Binding, Rats, Inbred SHR, Time Factors, Tissue Distribution, Transfection, Blotting, Northern, Signal Transduction, Calcitonin Gene-Related Peptide, Rats, Sprague-Dawley, Sequence Homology, Amino Acid, Receptors, Calcitonin Gene-Related Peptide, DNA, Complementary, Peptide Hormones, Cell Line, Tumor, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.